Catalent
The Catalent Applied Drug Delivery Institute has announced that Dr. Ralph Lipp a well-known pharmaceutical industry executive and inventor, will become the founding member of the Institute’s Advisory Board. Dr. Lipp brings over 20 years of industry and academic experience to the Institute, having previously served as Vice President, Pharmaceutical Sciences R&D, at Eli Lilly and Company, and in R&D leadership roles at Schering AG. He has brought dozens of new medical entities into clinical studies and contributed to launch of 10 new treatments. Dr. Lipp’s accomplishments include more than 20 patents, including five marketed medicines, and more than 100 additional scientific publications. His broad research experience includes oncology, cardiovascular disease, central nervous system disorders, women’s health, in vivo diagnostics and dermatology.
“I look forward to leveraging my experience and knowledge to help the Institute accomplish its important mission of delivering better treatments to patients,” Dr. Lipp commented. “I believe enhanced adaption of applied drug delivery technologies and increased collaboration across the industry and with academia will help innovator companies develop better products, resulting in improved outcomes for patients.” Dr. Lipp is currently President and CEO of Lipp Life Sciences, LLC.
The Institute also has appointed Ms. Terry Robinson as Executive Director. Since joining Catalent Pharma Solutions five years ago, Robinson has fostered countless collaborations with top pharmaceutical innovators, bringing business and scientific leaders together to help develop better treatments. She brings over 25 years of health care experience at Eli Lilly and Company and Amgen, Inc. to her new role leading the Institute. Robinson will work closely with the Institute’s Advisory Board to advance the use of drug delivery technologies to bring more and better treatments to patients via new technology development, increased cross-industry and academic collaborations, advanced industry education, research and publications.
“The welcome additions of Dr. Lipp and Ms. Robinson are a significant step in building a strong foundation for the Institute,” noted Dr. Kurt Nielsen, a Director of the Institute and Catalent’s SVP of R&D. “Terry’s ability to build collaborative partnerships, combined with the well-known drug development and delivery expertise of Dr. Lipp and other future Advisory Board members, will enable the Institute advance the future of drug delivery to improve patient treatments."
Catalent Applied Drug Delivery Institute, www.drugdeliveryinstitute.com.